Hepatitis C Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Hepatitis C Market is Segmented by Type (Diagnosis and Treatment), End-User (Hospitals and Clinics, Diagnostic Laboratories, and Other End-Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD) for the above segments.

Hepatitis C Market Size

Compare market size and growth of Hepatitis C Market with other markets in Healthcare Industry

Hepatitis C Market Analysis

The Hepatitis C Market is expected to register a CAGR of 12.82% during the forecast period.

  • The COVID-19 pandemic significantly impacted the hepatitis C market and influenced the market growth rate during the pandemic phase. For instance, according to a study published by the Journal of Managed Care & Specialty Pharmacy in June 2022, patients with hepatitis C (HCV) had poorer access to treatment. They were much less likely to complete the treatment course amid the COVID-19 pandemic. The study observed decreased adherence to HCV DAA therapy and laboratory monitoring through the outbreak phase.
  • Furthermore, the above study highlighted the telehealth option for patients in a post-COVID-19 environment that could provide an additional advantage in increasing access to care for patients with HCV. Hence, with better access to diagnosis and treatment post-COVID-19, the demand for hepatitis C tests and drugs observed a nominal increase. For instance, according to an article published by Inquiry in May 2023, the COVID-19 pandemic enhanced the use of telehealth to deliver services to those with hepatitis C virus (HCV), human immunodeficiency virus (HIV), and other chronic diseases in need of this type of care.
  • Additionally, there was a post-pandemic acceptability of pharmacist-delivered telehealth services among HCV and HIV monoinfected and coinfected patients. Thus, as per the analysis, the impact of COVID-19 was severe in the initial stages of the outbreak; however, with increased awareness and growth in the accessibility of digital options such as telehealth in the post-pandemic era, the market is anticipated to witness stable growth over the coming years.
  • Factors such as the growing disease burden of hepatitis C, increasing awareness and advances in diagnosis, and a surge in the availability of advanced therapeutic products are expected to drive market growth. For instance, according to the World Health Organization (WHO) update in June 2022, an estimated 58 million people had chronic hepatitis C virus infection, with about 1.5 million new infections occurring every year globally. An estimated 3.2 million adolescents and children had chronic hepatitis C infection. Thus, with a high burden of hepatitis C, the demand for its treatment and early diagnosis increases, leading to market growth.
  • Furthermore, according to an article published by Current Opinion in Infectious Diseases, in July 2022, direct-acting antiviral (DAA) regimens targeting hepatitis C virus (HCV) were approved for young children. Postpartum treatment programs prevent vertical transmission but are hampered by low linkage rates to care and treatment completion. These challenges were avoided by DAA use in pregnancy. Thus, with the advancement in treatment modalities for hepatitis C, the demand for these is also expected to increase, driving market growth.
  • Furthermore, May 2022 was observed as Hepatitis Awareness Month to raise awareness about, recognize the impact of, and decrease the stigma associated with viral hepatitis in the United States. Also, in September 2021, NACCHO partnered with NASTAD and the National Viral Hepatitis Roundtable to launch the Hepatitis Network for Education and Testing (HepNET) to identify and address the unmet needs of people who inject drugs (PWID) and improve their access to viral hepatitis education, prevention, testing, linkage to care, and treatment. Thus, with increasing awareness, the demand for hepatitis C diagnosis and treatment will likely increase, boosting market growth.
  • Thus, all factors mentioned above are expected to boost market growth over the forecast period. However, the higher cost of treatment, social stigma, and undiagnosed cases are restraining the market growth.

North America is Expected to Hold a Significant Share in the Hepatitis C Market

  • Due to an increase in hepatitis C infections and the commercial availability of hepatitis drugs in the region, North America is expected to hold a significant market share in the hepatitis C market. For instance, according to an article published by the American Hospital Association, in August 2022, over 2 million United States adults have hepatitis C virus infection each year. Infections are increasing by about 60,000 annually due to the opioid epidemic. Thus, with an increase in hepatitis C infection, the demand for its diagnosis and treatment is likely to increase, ultimately boosting the market growth in the region.
  • Furthermore, the presence of key market players, growing awareness programs, and the introduction of newer drugs and tests in the region bolster the market's growth in the North American region. For instance, in February 2022, the Task Force for Global Health sponsored a clinical trial to assess the outcomes of hepatitis C-affected mother-infant pairs exposed to direct-acting antivirals (DAAs) during pregnancy within a global clinical case registry. Additionally, in October 2021, AbbVie Inc. initiated a clinical trial in the United States to assess the adversative events and modifications in disease activity in adolescent and adult participants with acute hepatitis C virus (HCV) infection on treatment with oral tablets of Glecaprevir (GLE)/Pibrentasvir (PIB). Such instances are likely to favor the market growth in the region.
  • Thus, due to the abovementioned factors, North America is anticipated to witness notable growth over the forecast period.

Hepatitis C Industry Overview

The hepatitis C market is moderately concentrated in nature due to the presence of companies operating globally and regionally. The competitive landscape includes analyzing companies, including Gilead Sciences, Inc., AbbVie Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., and Novartis AG, among others.

Hepatitis C Market Leaders

  1. Gilead Sciences, Inc.

  2. AbbVie Inc.

  3. Bristol-Myers Squibb Company

  4. Merck & Co., Inc.

  5. Novartis AG

  6. *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF

Hepatitis C Market News

  • January 2023: HIVMA created guidance for treating patients with COVID-19 with nirmatrelvir-ritonavir (Paxlovid) who have HIV or hepatitis C. The guidance includes a link to IDSA's clinical guidance for using nirmatrelvir- ritonavir and potential drug interactions.
  • September 2022: Texas Medicaid designated MAVYRET medication as the primary preferred direct-acting antiviral (DAA) drug option for treating a hepatitis C infection.

Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Disease Burden of Hepatitis C
    • 4.2.2 Increasing Awareness and Advances in Diagnosis
    • 4.2.3 Surge In Availability of Advanced Therapeutic Products
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
    • 4.3.2 Social Stigma and Undiagnosed Cases
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Diagnosis
    • 5.1.1.1 Liver Biopsy
    • 5.1.1.2 Blood Tests
    • 5.1.1.3 Other Diagnoses
    • 5.1.2 Treatment
    • 5.1.2.1 Antiviral Drugs
    • 5.1.2.2 Immune Modulator Drugs
    • 5.1.2.3 Other Treatments
  • 5.2 By End-User
    • 5.2.1 Hospitals and Clinics
    • 5.2.2 Diagnostic Laboratory
    • 5.2.3 Other End-Users
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Gilead Sciences, Inc.
    • 6.1.2 AbbVie Inc.
    • 6.1.3 Bristol-Myers Squibb Company
    • 6.1.4 Merck & Co., Inc.
    • 6.1.5 Novartis AG
    • 6.1.6 Johnson & Johnson
    • 6.1.7 GlaxoSmithKline plc
    • 6.1.8 F. Hoffmann-La Roche Ltd
    • 6.1.9 Eli Lilly and Company
    • 6.1.10 Takeda Pharmaceutical Company Limited
    • 6.1.11 Cipla Inc.
    • 6.1.12 Daiichi Sankyo Company, Limited
    • 6.1.13 Astellas Pharma Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Hepatitis C Industry Segmentation

Hepatitis C is a viral infection that causes liver inflammation, sometimes leading to severe liver damage. Hepatitis C testing and therapeutic interventions are essential components in managing hepatitis C.

The hepatitis C market is segmented by type (diagnosis (liver biopsy, blood tests, and other diagnoses) and treatment (antiviral drugs, immune modulator drugs, and other treatments)), end-user (hospitals and clinics, diagnostic laboratories, and other end-users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.

The report offers the value (in USD) for the above segments.

By Type Diagnosis Liver Biopsy
Blood Tests
Other Diagnoses
Treatment Antiviral Drugs
Immune Modulator Drugs
Other Treatments
By End-User Hospitals and Clinics
Diagnostic Laboratory
Other End-Users
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Type
Diagnosis Liver Biopsy
Blood Tests
Other Diagnoses
Treatment Antiviral Drugs
Immune Modulator Drugs
Other Treatments
By End-User
Hospitals and Clinics
Diagnostic Laboratory
Other End-Users
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Frequently Asked Questions

What is the current undefined size?

The undefined is projected to register a CAGR of 12.82% during the forecast period (2025-2030)

Who are the key players in undefined?

Gilead Sciences, Inc., AbbVie Inc., Bristol-Myers Squibb Company, Merck & Co., Inc. and Novartis AG are the major companies operating in the undefined.

Which is the fastest growing region in undefined?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in undefined?

In 2025, the North America accounts for the largest market share in undefined.

What years does this undefined cover?

The report covers the undefined historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the undefined size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Our Best Selling Reports

Hepatitis C Industry Report

Statistics for the 2025 Hepatitis C market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Hepatitis C analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Hepatitis C Market Report Snapshots

Access Report